NCT03610646: A trial that was reported late by Mylan Pharmaceuticals Inc
This trial has reported, although it was 212 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03610646 |
|---|---|
| Title | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 23, 2018 |
| Completion date | Nov. 10, 2020 |
| Required reporting date | Nov. 10, 2021, midnight |
| Actual reporting date | June 10, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 212 |